Kenneth Hoberman
2016
In 2016, Kenneth Hoberman earned a total compensation of $3.3M as Chief Operating Officer at Stemline Therapeutics, a 88% increase compared to previous year.
Compensation breakdown
| Bonus | $214,245 |
|---|---|
| Option Awards | $1,466,022 |
| Salary | $428,490 |
| Stock Awards | $1,227,998 |
| Total | $3,336,755 |
Hoberman received $1.5M in option awards, accounting for 44% of the total pay in 2016.
Hoberman also received $214.2K in bonus, $428.5K in salary and $1.2M in stock awards.
Rankings
In 2016, Kenneth Hoberman's compensation ranked 2,809th out of 14,075 executives tracked by ExecPay. In other words, Hoberman earned more than 80.0% of executives.
| Classification | Ranking | Percentile |
|---|---|---|
All | 2,809 out of 14,075 | 80th |
Division Manufacturing | 974 out of 5,489 | 82nd |
Major group Chemicals And Allied Products | 287 out of 1,895 | 85th |
Industry group Drugs | 209 out of 1,538 | 86th |
Industry Pharmaceutical Preparations | 161 out of 1,176 | 86th |
Source: SEC filing on May 1, 2017.
Hoberman's colleagues
We found two more compensation records of executives who worked with Kenneth Hoberman at Stemline Therapeutics in 2016.